<DOC>
	<DOC>NCT01993927</DOC>
	<brief_summary>To determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent progression to type 2 diabetes mellitus in patients with impaired glucose tolerance in the routine clinical setting.</brief_summary>
	<brief_title>Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance "Long-term Use in Patients With Impaired Glucose Tolerance"</brief_title>
	<detailed_description>This is a special drug use surveillance on long-term use of Voglibose (Basen) designed to determine the safety and efficacy of long-term use of Voglibose (Basen) to prevent progression to type 2 diabetes mellitus in patients with impaired glucose tolerance in the routine clinical setting. Subjects will be patients with impaired glucose tolerance. The planned sample size is 1,000. The usual adult dosage is 0.2 mg of voglibose administered orally three times daily immediately before each meal.</detailed_description>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Patients must meet all of the following criteria ([1] to [3]) to be included in this study: 1. Determined as having IGT (defined as fasting blood glucose &lt; 126 mg/dL and 2hour post 75g oral glucose tolerance test [OGTT] blood glucose of 140199 mg/dL) without improvement despite treatment with diet therapy and exercise therapy for 36 months 2. Meets any of the following conditions: (i) Concurrently has hypertension*1 (ii) Concurrently has dyslipidemia*2 (iii) Is obese (BMI ≥25 kg/m2) (iv) Has a family history of diabetes mellitus in relatives to the second degree as defined by Japanese law*3 3. Regularly visits the study site and can be observed for 72 weeks 1: Hypertension: Patients with systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg, or patients on oral antihypertensive medication. 2: Dyslipidaemia: Patients with any of the following conditions or patients on oral antidyslipidemic medication Hyper LDL cholesterolemia (fasting LDLcholesterol ≥140 mg/dL) Hypo HDL cholesterolemia (fasting HDLcholesterol &lt; 40 mg/dL) Hypertriglyceridemia (fasting triglyceride ≥150 mg/dL) *3: Relatives to the second degree of consanguinity refer to blood relatives who are the subject's "father or mother, grandfather or grandmother, brothers or sisters, children, or grandchildren." Note that these do not include spouse's relatives. Patients meeting either of the following criteria ([1] or [2]) will be excluded: 1. Previously diagnosed with diabetes mellitus 2. Has any contraindications to Basen as specified below: (i) Severe ketosis, diabetic coma or precoma (ii) Severe infection, perioperative state, or serious trauma (iii) History of hypersensitivity to any ingredients of Basen</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>